ABBOTT LABORATORIES
Close on Oct 19, 2026
- Market cap
- $181.37B
- P/E (TTM)
- 33.5
- Dividend yield
- 2.31%
Earnings
Next report expected Oct 14, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 16, 2026 | Before market open | $12.59B | $0.53 | $1.31 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 16, 2026 | Before market open | $11.16B | $0.61 | $1.15 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 22, 2026 | Before market open | $11.46B | $1.01 | $1.50 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 15, 2025 | Before market open | $11.37B | $0.94 | $1.30 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 17, 2025 | Before market open | $11.14B | $1.01 | $1.26 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 16, 2025 | Before market open | $10.36B | $0.76 | $1.09 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 22, 2025 | Before market open | $11.00B | $5.27 | $1.34 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 16, 2024 | Before market open | $10.60B | $0.94 | $1.21 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 18, 2024 | Before market open | $10.40B | $0.74 | $1.14 |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 17, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 24, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 16, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| comparable sales growthnon-GAAP | full-year 2026 | 6.5% to 7.5% growth | Maintained |
| adjusted diluted earnings per sharenon-GAAP | full-year 2026 | $5.45 to $5.60 | Raised |
| adjusted diluted earnings per sharenon-GAAP | third-quarter 2026 | $1.38 to $1.46 | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Abbott Laboratories filed with the SEC
Abbott reaches agreements to resolve
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Results of operations · EX-99.1 to Form 8-K
IN THE UNITED STATES DISTRICT COURT
Other events · EX-99.1 to Form 8-K
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
Results of operations · EX-99.1 to Form 8-K
Abbott completes acquisition of Exact
Other events · EX-99.1 to Form 8-K
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Acquisition of Exact Sciences 20 | November | 2025
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Second-Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Second-Quarter 2024 Results and Raises
Results of operations · EX-99.1 to Form 8-K
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
Results of operations · EX-99.1 to Form 8-K
Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Third-Quarter 2022 Results and Raises
Results of operations · EX-99.1 to Form 8-K
Second-Quarter 2022 Results and Raises
Results of operations · EX-99.1 to Form 8-K
growth of 13.8 percent; organic sales growth of 17.5 percent
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
Results of operations · EX-99.1 to Form 8-K
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit
Results of operations · EX-99.1 to Form 8-K
Abbott to Sell Abbott Medical Optics to Johnson & Johnson for $4.325 Billion
Material agreement · Other events · EX-99.1 to Form 8-K
Abbott Reports Third-Quarter 2013 Results
Results of operations · EX-99.1 to Form 8-K
Abbott to Become No. 1
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Completes Acquisition of Advanced Medical Optics
Acquisition or disposition completed · New financial obligation · Other events · EX-99.1 to Form 8-K
NOTICE OF FUNDAMENTAL CHANGE AND
Acquisition or disposition completed · New financial obligation · Other events · EX-99.2 to Form 8-K
NOTICE OF FUNDAMENTAL CHANGE AND
Acquisition or disposition completed · New financial obligation · Other events · EX-99.3 to Form 8-K
Abbott Announces Earnings Guidance For 2009
Results of operations · EX-99.1 to Form 8-K
ABBOTT REPORTS 17.5 PERCENT SALES
Results of operations · EX-99.1 to Form 8-K
ABBOTT REPORTS 16.0 PERCENT SALES
Results of operations · EX-99.1 to Form 8-K